Zai Lab Ltd: management transactions · United States · SEC (Form 4)

About Zai Lab Ltd

Zai Lab Ltd (NASDAQ: ZLAB) is a U.S.-listed biopharmaceutical company trading on the NASDAQ market in the United States, with a dual operating footprint across the United States and China. For international investors, it fits the profile of a growth-oriented biotech platform that combines a commercial base in China with global research and development capabilities. The company was founded in 2014 by Dr. Samantha Du with the goal of building a leading global biopharma company able to discover, develop, and commercialize innovative therapies addressing major unmet medical needs. Its headquarters are in Cambridge, Massachusetts and Shanghai, underscoring a binational model that gives the company access to talent, capital, clinical infrastructure, and regulatory expertise in both markets. ([zailaboratory.com](https://www.zailaboratory.com/about-us/)) Zai Lab’s business model is built around in-licensed assets, strategic partnerships, and internally developed programs. The company operates across oncology, immunology, neuroscience, and infectious disease, and describes itself as a fully integrated biopharmaceutical company with capabilities spanning discovery, clinical development, regulatory affairs, manufacturing, and commercialization. In China, Zai Lab has built a meaningful commercial platform and states that it has eight products on the market, which provides a revenue base to support ongoing R&D investment. ([zailaboratory.com](https://www.zailaboratory.com/about-us/)) From a competitive standpoint, Zai Lab differentiates itself by combining local commercial execution in China with the ability to advance select assets globally. Its marketed portfolio includes ZEJULA, VYVGART, NUZYRA, and XACDURO, while the pipeline includes near-term launch and regulatory opportunities such as KarXT and TIVDAK. The company is also placing increasing strategic emphasis on zocilurtatug pelitecan, or “zoci,” a DLL3-targeted antibody-drug conjugate that management describes as a potential best-in-class and first-in-class asset in small cell lung cancer. In 2026, Zai Lab said KarXT launch preparations were underway, TIVDAK remained under regulatory review, and positive Phase 3 data for povetacicept and elegrobart created additional growth opportunities for the regional business. ([ir.zailaboratory.com](https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-first-quarter-2026-financial-results-and)) Geographically, the company operates with teams in the United States, Greater China, and Europe, and lists locations including Cambridge, San Francisco, San Diego, Beijing, Shanghai, Suzhou, Hong Kong, and Taiwan. That footprint supports a strategy that relies on cross-border R&D, regional regulatory execution, and commercialization in one of the world’s most important pharmaceutical markets. ([zailaboratory.com](https://www.zailaboratory.com/about-us/)) Recent developments have been material. In 2026, Zai Lab reported the China NMPA approval of COBENFY for adult schizophrenia, the NMPA approval of AUGTYRO for NTRK-positive solid tumors, the launch of a global Phase 3 study for zoci in second-line extensive-stage small cell lung cancer, and encouraging clinical data presented at AACR 2026. First-quarter 2026 revenue was $99.6 million, while cash, short-term investments, and current restricted cash totaled $761.3 million at March 31, 2026. For investors, Zai Lab offers exposure to China’s biopharma growth runway and a globally relevant pipeline, but with the clinical and regulatory risk typical of a NASDAQ-listed biotech company. ([ir.zailaboratory.com](https://ir.zailaboratory.com/news-releases/news-release-details/zai-lab-announces-first-quarter-2026-financial-results-and))